Corin Group Revenue and Competitors
Estimated Revenue & Valuation
- Corin Group's estimated annual revenue is currently $258.8M per year.
- Corin Group's estimated revenue per employee is $251,000
Employee Data
- Corin Group has 1031 Employees.
- Corin Group grew their employee count by 18% last year.
Corin Group's People
Name | Title | Email/Phone |
---|---|---|
1 | Executive Assistant supporting the CEO and US President | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Chief Technology Officer | Reveal Email/Phone |
5 | Chief People Officer | Reveal Email/Phone |
6 | Chief Operating Officer Corin Group | Reveal Email/Phone |
7 | Chief Quality and Regulatory Officer | Reveal Email/Phone |
8 | Chief R&D Officer | Reveal Email/Phone |
9 | Head Marketing GSA | Reveal Email/Phone |
10 | Head FP&A - Europe | Reveal Email/Phone |
Corin Group Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $86.6M | 345 | 2% | N/A | N/A |
#2 | $369.5M | 920 | -23% | $974.7M | N/A |
#3 | $1M | 4 | 0% | N/A | N/A |
#4 | $258.8M | 1031 | 18% | N/A | N/A |
#5 | $136M | 542 | 8% | N/A | N/A |
#6 | $19.8M | 79 | -2% | N/A | N/A |
#7 | $51.7M | 206 | 7% | N/A | N/A |
#8 | $40.9M | 163 | 10% | N/A | N/A |
#9 | $85.1M | 339 | 9% | N/A | N/A |
#10 | $40.4M | 161 | 8% | N/A | N/A |
What Is Corin Group?
As a leader in orthopaedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company's talented and dedicated teams share a common commitment to deliver quality orthopaedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives. With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin's product portfolio is designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance. Applying our in-house knowledge and experience, coupled with the know-how of eminent surgeons, Corin's innovative product offering today includes a wide range of cutting edge brands. Alongside Trinity advanced bearing acetabular cup, MiniHip conservative stem, TriFit TS cementless tapered stem, MetaFix cementless stem and TaperFit cemented stem, Corin's pioneering hip portfolio also incorporates ECiMa next generation vitamin E highly cross-linked polyethylene and Biomimetic Cementless Technology. Unity Knee is the most recent addition to our knee portfolio, which also encompasses Uniglide unicompartmental knee and Rotaglide+ total knee. Unity brings a new dimension to patients and surgeons, helping to address long-standing issues of patient satisfaction and wear. Within our wider product portfolio and further extending our range of advanced treatment options, Zenith total ankle replacement and LARS soft tissue internal fixation also play an important role in bringing quality of life to patients.
keywords:Biotechnology,Healthcare,Medical DevicesN/A
Total Funding
1031
Number of Employees
$258.8M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Corin Group News
... Key Player SWOT Analysis and Forecast to 2028 Top Industry Players as Exactech, Inc, MicroPort Scientific Corporation, Corin Group.
Artificial Ligaments Market Size, Share, Growth 2022-2030| Key Players Corin Group, Orthomed, Neoligaments, Shanghai Songli Bioitech.
... Shanghai Pine&Power Biotech, Mathys AG Bettlach, FX Solutions, Cousin Biotech, Arthrex Inc., Corin Group, Lars, Stryker Corporation.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $345.1M | 1700 | 49% | N/A |
#2 | $1691.1M | 5752 | 2% | N/A |